Citations

Clear

4799 citation(s) found for "Yu, Jennifer".

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Armstrong, Deborah K. , Alvarez, Ronald D. , Barroilhet, Lisa , Berek, Jonathan S. , Cristea, Mihaela , DeRosa, Marie, ElNaggar, Adam C. , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Liu, Joyce F. , Mahdi, Haider , Matei, Daniela , McHale, Michael , O’Malley, David M. , Penson, Richard T. , Percac‐Lima, Sanja , Ratner, Elena , Remmenga, Steven W., Sabbatini, Paul , Werner, Theresa L. , Zsíros, Emese , Burns, Jennifer L. , Engh, Anita M. , Matei, Daniela E , O'Malley, David M , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , Chen, Lee-may , Gershenson, David M. , Johnston, Carolyn , Leath, Charles A , McLean, Karen

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2019 | Volume: 17 | Issue: 8 | Pages: 896-909

10.6004/jnccn.2019.0039 | PMID 31390583 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.
Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population
Hlavacek, Patrick , Rosenblatt, Lisa, Keshishian, Allison , Russ, Cristina , Mardekian, Jack , Ferri, Mauricio , Poretta, Tayla, Yüce, Hüseyin , Guo, Jennifer D. , McBane, Robert D.

Mayo Clinic

Current Medical Research and Opinion | August 7, 2019 | Volume: 35 | Issue: 12 | Pages: 2043-2051

10.1080/03007995.2019.1653067 | PMID 31387467 Get It

Peer support: A needs assessment for social support from trained peers in response to stress among medical physicists
Johnson, Jennifer , Ford, Eric , Yu, James B. , Buckey, Courtney, Fogh, Shannon , Evans, Suzanne B. , Evans, Suzanne , Yu, James B

Mayo Clinic

Journal of Applied Clinical Medical Physics | July 29, 2019 | Volume: 20 | Issue: 9 | Pages: 157-162

10.1002/acm2.12675 | PMID 31355990 Get It

AbstractPurposePrevious studies suggest that within radiation oncology, medical physicists (MP) experience high workloads. Little is known about how MPs use social support (SS) in times of stress.MethodsIn collaboration with the Workgroup on Prevention of Medical Error, the American Association of Physicists in Medicine administered this Human Investigation Committee (HIC) approved email survey to 8566 members. Respondents were considered likely to seek SS if they answered (probably/definitely would) and unlikely to seek support if they answered (probably/definitely would not). Logistic regression was applied to determine associations between demographic factors and willingness to seek support as well as perception of barriers.ResultsOne thousand two hundred and ninety‐seven members (15.1%) accessed and gave consent for the survey. One thousand and one (11.7%) respondents answered all relevant questions. Respondents were predominantly male (69.1%), MP in radiation oncology (81.8%), private practice (51.6%), with practice duration> 10 yr (60.2%). MPs were likely to seek SS for personal physical illness (78.63%), involvement in a medical error (73.94%) or adverse patient outcome (75.17%). MPs sought SS in the setting of personal fatigue (33.2%) or burnout (44.3%). Barriers to seeking SS were lack of time (80.3%), and uncertainty about whom to access (70.7%). MPs responded that they would be most likely to seek support from an equally experienced medical physicist colleague (81.0%). Most MPs (67.0%) identified as having experienced stressors, with serious family illness (35.2%), or burnout (32.8%) being most common. Factors associated with MPs unwillingness to seek SS for medical error included> 20 yr in practice (vs still in training — OR 0.30, P = 0.015), and male gender (OR 0.60, P = 0.003). Male gender was associated with the lowest willingness to seek support (OR 2.10, P = 0.0001), but also with fewer perceived barriers (OR 1.60, P = 0.0075).ConclusionWillingness to seek SS is demonstrated, and MPs want colleagues to provide support. Given these results, peer support could be considered among MPs.
Postoperative Recovery Comparisons of Arthroscopic Bankart to Open Latarjet for the Treatment of Anterior Glenohumeral Instability
Smith, Jennifer , Higgins, Laurence D. , Woodmass, Jarret Murray , Wagner, Eric R. , Warner, Jon J.P.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | July 29, 2019 | Volume: 7 | Issue: 7_suppl5 | Pages: No page available

10.1177/2325967119s00272 Get It

Objectives: Recurrent anterior glenohumeral instability is a disabling pathology that can be successfully treated by arthroscopic Bankart repair or an open Latarjet procedure. Long-term outcomes have shown lower rates of apprehension, recurrent dislocation and operative revision following Latarjet when compared to Bankart repair. However, there is a paucity of studies comparing the short-term post-operative recovery of arthroscopic Bankart versus open Latarjet. The purpose of this study is to evaluate the post-operative recovery following Bankart and the open Latarjet procedure. Methods: The surgical outcomes system (SOS) database (Arthrex Inc., Naples, FL) was used to compare the post-operative recovery outcomes after either a primary or revision arthroscopic Bankart and an open Latarjet procedure. Patients were included who had a minimum of 1 year follow-up. Preoperative and postoperative (2 weeks, 6 weeks, 3 months, 6 months, 1 year and 2 year) time points were evaluated. Outcomes measures included Visual Analog Pain Scale (VAS), American Shoulder and Elbow Surgeons (ASES) Shoulder Function Score, ASES Shoulder Index Score, and SANE Score. Overall, 787 patients underwent primary Bankart (518 male, 240 female, 4 not recorded), 36 underwent revision Bankart (24 male, 10 female, 2 not recorded) and 75 underwent an open Latarjet procedure (59 male, 12 female, 4 not recorded). The mean age for primary Bankart, revision Bankart, and open Latarjet was 40.8, 38.6 and 32.8 respectively. Additionally, the average BMI for primary Bankart, revision Bankart, and open Latarjet was 27.2, 28.13, and 25.6, respectively. Results: The postoperative recovery curves are displayed in Figure 1. When compared to primary Bankart, open Latarjet demonstrated significantly lower VAS scores at six weeks (p=0.0272) and at three months (p=0.0094). Medium term outcomes for ASES Shoulder Index Score, ASES Shoulder Function Score, and SANE Score, at 1- and 2-years showed no difference between primary Bankart and Latarjet. For the revision Bankart and open Latarjet procedures, the open Latarjet cohort demonstrated significantly higher ASES Shoulder Index Scores at the 3-months (p= 0.0017), 1-year (p= 0.0021), and 2-years (p= 0.0006) timepoints. Open Latarjet patients also had significantly higher ASES Shoulder Function Scores than revision Bankart at 3-months (p= 0.0162), 1-year (p= 0.0083), and 2-years (p= 0.0013). Revision Bankart repair resulted in significantly higher VAS scores than open Latarjet at 2-weeks (p= 0.0025), 6-weeks (p=0.0114), 3-months (p= 0.0024), 1-year (p= 0.0039), and 2-years (p= 0.0007). Conclusion: When compared to Bankart repair, open Latarjet provides improved pain and functional outcomes during the early recovery phase, 2-weeks, 6-weeks, 3-months, and 6-months, with equivalent medium-term outcomes at 1-2-years. Furthermore, when compared to revision Bankart reconstruction, open Latarjet provides improved ASES Shoulder Index Scores, ASES Shoulder Function Scores and VAS Scores at nearly all timepoints. In the treatment of recurrent anterior glenohumeral instability, open Latarjet is reasonable option in the primary setting and should be favored over Bankart repair for revision cases with improved pain relief and functional scores.
Experience and expectations of patients on weight loss: The Learning Health System Network Experience
DeJesus, Ramona S. , Bradley, David , Haller, Irina V. , Schroeder, Darrell R. , Sauver, Jennifer L. St. , Phelan, Sean M. , Croghan, Ivana T. , DeJesus, R S , Phelan, S M , St Sauver, Jennifer L , Schroeder, Darrell , Bauer, Katherine W. , Bradley, Steven M.

Mayo Clinic

Obesity Science & Practice | July 26, 2019 | Volume: 5 | Issue: 5 | Pages: 479-486

10.1002/osp4.364 | PMID 31687172 Get It

SummaryObjectiveWeight perception and degree of confidence in achieving healthy lifestyle can be determinants of engagement in obesity interventions. This study explored patients' perceived need for weight loss and the degree of self‐confidence in ability to lose weight and sought to identify factors associated with patients' self‐confidence in ability to lose weight.MethodsThe authors analysed data from a survey mailed to primary care patients within five sites of the Learning Health Systems Network that explored participants' prior experience with weight management.ResultsAmong the 2,263 participants who completed the survey section on ‘Patients’ Experience with Weight Management’, perceived need to lose 51 lb or more was statistically significant among those with class III obesity compared with other body mass index (BMI) groups (p value < 0.001). Reported desire to lose weight was also significantly higher among those with the highest BMI than those who were overweight (p value < 0.001). However, this same group had the lowest belief in ability to lose weight (p value < 0.001). In a multiple regression analysis, female gender, higher BMI and need to lose >10 lb were each independently associated with less belief in being able to lose weight.ConclusionsPatients had varying perceptions on weight loss; those with category III obesity had the highest desire to lose weight but had the least confidence in ability to lose weight. Higher BMI, female gender and need to lose >10 lb were associated with decreased self‐confidence in ability to lose weight.
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer
Norden, Andrew D., Henk, Henry J. , Mansfield, Aaron S. , Arunajadai, Srikesh, Carnahan, Ryan M. , Christian, Jennifer , Torres, Aracelis Z. , Mansfield, Aaron S , Stewart, Mark D. , Dreyer, Nancy A , Abernethy, Amy P. , Chrischilles, Elizabeth A. , Kushi, Lawrence H. , Khozin, Sean , Sharon, Elad , Miksad, Rebecca Anne , Sakoda, Lori C. , Valice, Emily , Allen, Jeff D.

Mayo Clinic

JCO Clinical Cancer Informatics | July 23, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-15

10.1200/cci.18.00155 | PMID 31335166 Get It

PURPOSE This pilot study examined the ability to operationalize the collection of real-world data to explore the potential use of real-world end points extracted from data from diverse health care data organizations and to assess how these relate to similar end points in clinical trials for immunotherapy-treated advanced non–small-cell lung cancer. PATIENTS AND METHODS Researchers from six organizations followed a common protocol using data from administrative claims and electronic health records to assess real-world end points, including overall survival (rwOS), time to next treatment, time to treatment discontinuation (rwTTD), time to progression, and progression-free survival, among patients with advanced non–small-cell lung cancer treated with programmed death 1/programmed death-ligand 1 inhibitors in real-world settings. Data sets included from 269 to 6,924 patients who were treated between January 2011 and October 2017. Results from contributors were anonymized. RESULTS Correlations between real-world intermediate end points (rwTTD and time to next treatment) and rwOS were moderate to high (range, 0.6 to 0.9). rwTTD was the most consistent end points as treatment detail was available in all data sets. rwOS at 1 year post–programmed death-ligand 1 initiation ranged from 40% to 57%. In addition, rwOS as assessed via electronic health records and claims data fell within the range of median OS values observed in relevant clinical trials. Data sources had been used extensively for research with ongoing data curation to assure accuracy and practical completeness before the initiation of this research. CONCLUSION These findings demonstrate that real-world end points are generally consistent with each other and with outcomes observed in randomized clinical trials, which substantiates the potential validity of real-world data to support regulatory and payer decision making. Differences observed likely reflect true differences between real-world and protocol-driven practices.
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE
Perez, Edith A. , Barrios, Carlos H. , Eiermann, W., Im, Young‐Hyuck , Conte, PierFranco , Pieńkowski, Tadeusz , Burris, Howard A. , Petersen, Jennifer, Haas, Sanne de , Hoersch, Silke, Patre, Monika, Ellis, Paul Anthony, Conte, Pierfranco , Toi, Masakazu , Martín, Miguel , Pivot, Xavier B. , Petersen, Jennifer A.

Mayo Clinic

Cancer | July 18, 2019 | Volume: 125 | Issue: 22 | Pages: 3974-3984

10.1002/cncr.32392 | PMID 31318460 Get It

Background In the phase 3 MARIANNE trial, trastuzumab emtansine (T‐DM1) with or without pertuzumab showed noninferior progression‐free survival and better tolerability than trastuzumab plus a taxane (HT) for the first‐line treatment of human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer. This article reports the final descriptive overall survival (OS) analysis, updated safety data, and additional patient‐reported outcomes and biomarker analyses. Methods OS was assessed in 1095 patients with HER2‐positive breast cancer and no prior therapy for advanced disease who had been randomized to HT, T‐DM1 plus a placebo (hereafter T‐DM1), or T‐DM1 plus pertuzumab (T‐DM1+pertuzumab). A post hoc exploratory landmark analysis of OS, baseline patient and disease characteristics, and tumor biomarkers in patients with and without an objective tumor response (OR) according to the Response Evaluation Criteria in Solid Tumors within 6.5 months of randomization was conducted. Results The median OS was similar across groups (50.9, 53.7, and 51.8 months for the HT, T‐DM1, and T‐DM1+pertuzumab groups, respectively). Among patients with an OR, the median OS was longer with T‐DM1 (64.4 months) and T‐DM1+pertuzumab (not reached) versus HT (56.3 months). No baseline characteristics or biomarkers were strongly associated with OR. The incidence of grade 3 or higher adverse events was greater with HT (55.8%) than T‐DM1 (47.1%) or T‐DM1+pertuzumab (48.6%). The median time to clinically meaningful deterioration (a 3‐point or greater change) in neurotoxicity symptoms was shorter with HT (2.1 months) and T‐DM1+pertuzumab (4.2 months) than T‐DM1 (6.2 months). Fewer patients reported alopecia and diarrhea and were bothered by treatment side effects in the T‐DM1 arm. Conclusions These results support T‐DM1 as a first‐line treatment for patients with HER2‐positive metastatic breast cancer who are deemed unsuitable for taxane‐based therapy.
Comparison of eVisit Management of Urinary Symptoms and Urinary Tract Infections with Standard Care
Murray, Martha A. , Penza, Kristine S , Myers, Jane F., Furst, Joseph W. , Pecina, Jennifer L. , Pecina, Jennifer

Mayo Clinic

Telemedicine and e-Health | July 17, 2019 | Volume: 26 | Issue: 5 | Pages: 639-644

10.1089/tmj.2019.0044 | PMID 31313978 Get It

Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry
Cammann, Victoria L. , Sarcon, Annahita, Ding, Katharina J., Kato, Ken , Vece, Davide Di , Szawan, Konrad A. , Gili, Sebastiano , Jurisic, Stjepan , Bacchi, Beatrice , Micek, Jozef, Frangieh, Antonio H. , Napp, L. Christian , Bossone, Eduardo , Citro, Rodolfo , Franke, Jennifer , Knorr, Maike, Heiner, Susanne, Burgdorf, Christof , Köenig, Wolfgang , Tschöpe, Carsten , Rajan, Lawrence, Michels, Guido, Pfister, Roman , Cuneo, Alessandro , Jacobshagen, Claudius, Karakas, Mahir , Banning, Adrian , Cuculi, Florim , Kobza, Richard , Fischer, Thomas, Vasankari, Tuija , Airaksinen, Juhani , Dworakowski, Rafał , Osswald, Stefan , Galiuto, Leonarda , Dichtl, Wolfgang , Delmas, Clément , Horowitz, John D. , Kozel, Martin , Widimský, Petr, Winchester, David E. , Gilyarova, Ekaterina, Gilyarov, Mikhail , El‐Battrawy, Ibrahim , Akın, İbrahim , Ukena, Christian , Pieske, Burkert , Rottbauer, Wolfgang , Opolski, Grzegorz , MacCarthy, Philip , Felix, Stephan B. , Borggrefe, Martin , Crea, Filippo , Katus, Hugo A. , Münzel, Thomas , Böhm, Michael , Prasad, Abhiram , Shinbane, Jerold S., Lüscher, Thomas F. , Ghadri, Jelena R. , Templin, Christian , Gilyarov, Mikhail , Bossone, Eduardo , Citro, Rodolfo , El-Battrawy, Ibrahim , Prasad, Abhiram , Tschöpe, Carsten , Koenig, Wolfgang , Banning, Adrian , Kobza, Richard , Gilyarov, Mikhail , Ukena, Christian , Seifert, Burkhardt , Jaguszewski, Miłosz , D’Ascenzo, Fabrizio , Noutsias, Michel , Thiele, Hölger , Kaiser, Christoph A. , Lairez, Olivier , Toušek, Petr , Shilova, Alexandra S. , Bauersachs, Johann , Hasenfuß, Gerd , Braun-Dullaeus, Ruediger Christian , Mario, Carlo Di , Schunkert, Heribert , Bax, Jeroen J. , Ruschitzka, Frank T.

Mayo Clinic

Journal of the American Heart Association | July 17, 2019 | Volume: 8 | Issue: 15 | Pages: No page available

10.1161/jaha.118.010881 | PMID 31311438 Get It

Background Clinical characteristics and outcomes of takotsubo syndrome ( TTS ) patients with malignancy have not been fully elucidated. This study sought to explore differences in clinical characteristics and to investigate short‐ and long‐term outcomes in TTS patients with or without malignancy. Methods and Results TTS patients were enrolled from the International Takotsubo Registry. The TTS cohort was divided into patients with and without malignancy to investigate differences in clinical characteristics and to assess short‐ and long‐term mortality. A subanalysis was performed comparing long‐term mortality between a subset of TTS patients with or without malignancy and acute coronary syndrome (ACS) patients with or without malignancy. Malignancy was observed in 16.6% of 1604 TTS patients. Patients with malignancy were older and more likely to have physical triggers, but less likely to have emotional triggers compared with those without malignancy. Long‐term mortality was higher in patients with malignancy ( P <0.001), while short‐term outcome was comparable ( P =0.17). In a subanalysis, long‐term mortality was comparable between TTS patients with malignancies and ACS patients with malignancies ( P =0.13). Malignancy emerged as an independent predictor of long‐term mortality. Conclusions A substantial number of TTS patients show an association with malignancy. History of malignancy might increase the risk for TTS , and therefore, appropriate screening for malignancy should be considered in these patients. Clinical Trial Registration URL : http://www.clinicaltrial.gov . Unique identifier: NCT 01947621.